Amdocs (DOX) Reports Q4 Earnings: What Key Metrics Have to Say

12.11.25 00:00 Uhr

Werte in diesem Artikel
Aktien

64,50 EUR -0,92 EUR -1,41%

Amdocs (DOX) reported $1.15 billion in revenue for the quarter ended September 2025, representing a year-over-year decline of 9%. EPS of $1.83 for the same period compares to $1.70 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.14 billion, representing a surprise of +0.68%. The company delivered an EPS surprise of +0.55%, with the consensus EPS estimate being $1.82.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Amdocs performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenue- North America: $762.4 million versus $747.81 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -8.8% change.Geographic Revenue- Rest of the World: $208 million compared to the $220.41 million average estimate based on two analysts. The reported number represents a change of -14.8% year over year.Geographic Revenue- Europe: $179.8 million versus the two-analyst average estimate of $172.12 million. The reported number represents a year-over-year change of -2.3%.Revenue- Managed Services Revenue: $748.3 million versus $744.28 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.7% change.View all Key Company Metrics for Amdocs here>>>Shares of Amdocs have returned +5% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amdocs Limited (DOX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Amdocs

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amdocs

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Amdocs LtdShs

Wer­bung

Analysen zu Amdocs LtdShs

DatumRatingAnalyst
31.01.2018Amdocs BuyStifel, Nicolaus & Co., Inc.
12.11.2015Amdocs Equal WeightBarclays Capital
11.11.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
10.09.2015Amdocs OutperformOppenheimer & Co. Inc.
30.07.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
31.01.2018Amdocs BuyStifel, Nicolaus & Co., Inc.
11.11.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
10.09.2015Amdocs OutperformOppenheimer & Co. Inc.
30.07.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
19.03.2015Amdocs OutperformOppenheimer & Co. Inc.
DatumRatingAnalyst
12.11.2015Amdocs Equal WeightBarclays Capital
14.01.2011Amdocs neutralGoldman Sachs Group Inc.
22.07.2010Amdocs neutralWedbush Morgan Securities Inc.
19.07.2010Amdocs equal-weightBarclays Capital
23.04.2010Amdocs "hold"Kaufman Bros., LP
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amdocs LtdShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen